SignalHF vs Sepsis ImmunoScore
AI Verdict
Choose SignalHF if…
Choose SignalHF if your organization focuses on proactive management of chronic heart failure patients and aims to reduce hospital readmissions. This tool is ideal for clinics and hospitals managing patients with cardiac implantable electronic devices (CIEDs), as it leverages device data to predict heart failure hospitalizations within 30 days, enabling timely interventions and personalized care plans.
View SignalHF →Choose Sepsis ImmunoScore if…
Choose Sepsis ImmunoScore if your acute care setting requires rapid and precise diagnostic support for sepsis. This tool is best suited for emergency departments and ICUs where early identification and risk stratification of sepsis patients are critical, as it provides an FDA-authorized AI diagnostic that analyzes EHR data to predict adverse outcomes within 24 hours, guiding faster treatment decisions.
View Sepsis ImmunoScore →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | SignalHF | Sepsis ImmunoScore |
|---|---|---|
| Pricing | Contact for pricing | Enterprise subscription model |
| Deployment | SaaS | Integrated into hospital EHR/EMR systems |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Sepsis ImmunoScoreSepsis ImmunoScore's direct integration into hospital EHR/EMR systems streamlines clinician workflow by reducing context switching. Its intuitive display, which transparently explains how parameters contribute to the score, also enhances trust and ease of use for clinicians. SignalHF offers a unified platform and alert management, but direct EHR integration is a significant advantage for usability in acute care settings.
Clinical Value
Sepsis ImmunoScoreBoth tools are FDA-cleared/authorized and address critical clinical needs. Sepsis ImmunoScore, as the first FDA-authorized AI diagnostic for sepsis, provides rapid risk assessment and predicts a broad range of adverse outcomes (mortality, length of stay, ICU admission) within 24 hours for a life-threatening condition. SignalHF predicts heart failure hospitalizations within 30 days, which is valuable for early intervention, but the immediate and severe nature of sepsis, coupled with comprehensive outcome prediction, gives Sepsis ImmunoScore a slight edge in acute clinical impact.
Pricing & Value
TieNeither tool provides transparent pricing details in the structured facts. SignalHF states 'Contact for pricing,' while Sepsis ImmunoScore mentions an 'Enterprise subscription model' and an exclusive distribution partnership with Roche Diagnostics. Without specific pricing information or detailed value propositions, it is not possible to definitively determine a winner in this dimension.
Enterprise Readiness
Sepsis ImmunoScoreBoth tools demonstrate strong foundational enterprise readiness with FDA clearance, HIPAA compliance, and BAA agreements. However, Sepsis ImmunoScore's direct integration into hospital EHR/EMR systems and its exclusive distribution partnership with Roche Diagnostics indicate a more robust and streamlined path for enterprise-level deployment and support within large healthcare organizations. SignalHF's SaaS deployment and manufacturer-agnostic compatibility are also strong, but the direct EHR integration and major partnership for Sepsis ImmunoScore are key differentiators for large-scale adoption.
Innovation
Sepsis ImmunoScoreBoth tools represent significant innovation in healthcare AI. Sepsis ImmunoScore stands out as the 'first FDA-authorized AI diagnostic for sepsis,' a critical and complex condition, leveraging 22 diverse parameters for comprehensive risk assessment. Its transparent explanation of how parameters contribute to the score also highlights advanced AI/ML application. SignalHF's manufacturer-agnostic compatibility for CIED data is also innovative, but the pioneering 'first FDA-authorized' status in sepsis gives ImmunoScore a slight lead.
Support & Docs
TieThe provided structured facts do not offer specific details on support and documentation for either tool. While web searches indicate both companies offer customer support and training for their platforms, there isn't enough granular information to distinguish between the two definitively. Therefore, based on the available data, this dimension is a tie.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | SignalHF | Sepsis ImmunoScore |
|---|---|---|
| Name | SignalHF | Sepsis ImmunoScore |
| Company | Implicity | Prenosis |
| Description | FDA-cleared AI algorithm that predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices, enabling early intervention and personalized care. | First FDA-authorized AI diagnostic for sepsis, providing rapid risk assessment and prediction of adverse outcomes. It analyzes 22 parameters from EHRs to generate a risk score and four risk categories, aiding clinicians in faster treatment decisions and improved patient outcomes. |
| Primary Clinical Focus | Heart Failure | Sepsis |
| Data Sources | Various cardiac implantable electronic devices (CIEDs) data (physiological data, demographics, lead measurements, episodes, and therapies) | 22 parameters from EHRs (biomarkers and clinical data) |
| Key Output | Prediction of heart failure hospitalizations within 30 days, automatic alerts based on risk scores | Risk score and four discrete risk categories; prediction of risk of deterioration (length of stay, in-hospital mortality, ICU admission, mechanical ventilation, vasopressor use) within 24 hours |
Videos
Demos, reviews, and walkthroughs featuring SignalHF and Sepsis ImmunoScore.